In Brief: FDA reform
This article was originally published in The Rose Sheet
FDA reform: House hearings on FDA reform legislation are now targeted for May 1-2. A bill addressing foods sponsored by Rep. Scott Klug (R-Wis.), one of three FDA reform measures introduced March 29, would substitute the Delaney clause's zero-risk standard for food and color additives and animal drugs with a negligible, or de minimus, risk standard. In an analysis of the bill by Democratic staffers, the Delaney clause section is described as "highly controversial and...complicated." Supporters of the Senate FDA reform bill (S 1477), sponsored by Nancy Kassebaum (R-Kan.), hope to bring that bill to the Senate floor the first week in May...
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
Weekly Trademark Review